Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

eFFECTOR Therapeutics slumps on plans to stop development of lung cancer therapy

** Shares of eFFECTOR Therapeutics  EFTR.O  fall 78.6% to a
record low of $3.53 
    ** Co says that it will discontinue development of its
experimental therapy tomivosertib in non-small cell lung cancer
(NSCLC)
    ** EFTR says that while there was modest activity from
tomivosertib in the mid-stage study, it does not see an obvious
path forward to continue development 
    ** Co says there were 67% treatment emergent adverse events
for tomivosertib in combination with Merck's  MRK.N  cancer drug
Keytruda vs 37% for placebo plus Keytruda 
    ** NSCLC is the most common form of lung cancer
    ** YTD, stock down ~69.8%

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))

Recent news on Effector Therapeutics

See all news